A combination of new biotechnology research techniques and manufacturing technologies has reinvigorated the global vaccines industry. Vaccines are now targeting larger markets following increasing demand and improved profitability. The WHO estimates that more than 75 vaccines are currently at various stages of development for a range of diseases including AIDs, diarrhoea, pneumococcal disease, cervical cancer and smoking.

This report provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key growth areas and leading products through to 2014. The competitive landscape of the market is examined, based on an analysis of portfolio performance, pipeline strength and growth strategies for each major vaccine manufacturer.

This report also reviews the factors and underlying trends that are currently shaping market development, and provides forecasts for currently marketed and key pipeline products over the 2009-14 period.

Key Findings

The global vaccines market generated sales of $11.1bn in 2008, an increase of 0.5% over 2007. Merck/Sanofi-Aventis’ Gardasil led the market with sales of $1.6bn in 2008, while Wyeth’s Prevnar followed with $1.4bn. The top 10 brands accounted for 56.7% of the market.

Pneumococcal vaccines led the pediatric vaccines segment in 2008, with Wyeth’s Prevnar accumulating sales of $1.4bn. These were followed by DTP vaccines led by GSK’s Infanrix Hexa, which registered $281m sales. Emerging segments in the pediatric space include MMRV (MMR+ varicella), rotaviral and meningococcal vaccines.

HPV vaccines formed the single largest adult vaccines segment in 2008 with Merck/Sanofi-Aventis’ Gardasil posting sales of $1.6bn. These were followed by the fragmented influenza segment, which continues to be a major sales driver for vaccine developers. Hepatitis vaccines also captured a major share of the adult vaccines market.

Wyeth’s Prevnar 13vPnC and Novartis’ Menveo are among the most promising vaccines in the industry pipeline. GSK’s Cervarix is likely to attain blockbuster status in 2011, having received approval in the US market. The latter part of the forecast period will witness the launch of Novartis’ MenB, for the prevention of Neisseria meningitidis serogroup B infection.

Use this report to:

- Quantify infant, catch up, adolescent, adult and elderly vaccine target populations across France, Germany, Italy, Spain, the UK, the US, Japan, South Korea, Turkey, Russia, Mexico, Brazil, China and India.

- Assess leading pediatric and adult vaccine brands across major indications based on efficacy, adverse effects and ongoing trials, and evaluate the impact of recent events upon product performance.

- Compare the market performance and strategic positioning of major vaccine companies’ product portfolios with this report’s evaluation of the franchises of Merck, GSK, Wyeth, Sanofi-Aventis and Novartis.

- Forecast sales for key currently marketed and leading pipeline vaccines over the period 2009–14, assess the latest trends influencing R&D and measure the developmental progress of DNA and therapeutic vaccines.

Explore issues including:

The impact of prophylactic cancer vaccines. Since the launch of Merck’s Gardasil and GSK’s Cervarix, the market has expanded to include prophylactic vaccines against cancer. These vaccines have registered revenues of almost $1.8bn since launch.

The emergence of therapeutic vaccines. Therapeutic vaccines will redefine the vaccines market, which has predominantly been prophylactic in nature until date. Considering the unavailability of comprehensive therapeutic measures for indications such as cancer and HIV/AIDS, these therapy areas are a top priority for those developing such vaccines.

Next generation vaccine engineering. The vaccines market has transitioned from traditional egg-based cultures and aluminum adsorption techniques to large scale cell culture-based production and targeted adjuvant technology. Influenza vaccine makers are concentrating on cell culture-based production to meet the rising demand for these vaccines.

Sales potential for seasonal influenza vaccines. Despite the large number of players in the seasonal influenza market, the segment holds significant market opportunity due to an insufficient supply of vaccines. The demand for influenza vaccines is substantial when considering the requirement for coverage across all population segments.

Discover:

- What will be the major growth indications in the vaccines market over 2009–14?

- What are the current trends across DTP, pneumococcal, MMR, rotaviral, meningococcal, hepatitis, influenza, HPV and other infections within the seven major markets?

- What are the most promising candidate vaccines currently in clinical development?

- What is the commercial potential of key pipeline candidates through to 2014?

- Which companies are best positioned to succeed in the vaccines market over 2009–14?

- What is the forecast market size and growth rate over the period 2009–14 across the global vaccines market?

- What are the significant market and pipeline developments that may shape the corporate strategies of leading companies?


Table of Contents



155 pages

Publication Date : July 2009